Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Cynata Therapeutics Limited ( (AU:CYP) ).
Cynata Therapeutics Limited has reported a change in the interests of its director, Dr. Paul K Wotton, in the company’s securities. This change involves the conversion of 69,767 listed options into ordinary shares. The move signifies a potential realignment of interests or strategic decision by the director, which may have implications for his engagement with the company and could reflect his confidence in its future prospects.
More about Cynata Therapeutics Limited
YTD Price Performance: -27.37%
Average Trading Volume: 3,300
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $34.42M
Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.
